Skip to main content
. 2009 Oct 9;1:119–130. doi: 10.2147/cmr.s4721

Figure 2.

Figure 2

Overall survival in the AZA-001 trial by intention-to-treat analysis.

Reprinted from Lancet Oncol, 10, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase II study, 223–232,48 Copyright © 2009, with permission from Elsevier.

Abbreviation: CCR, conventional care regimens.